SCHEMBL405713

SCHEMBL405713

O=C(O)c1cccc2nc(Cc3cccnc3)[nH]c(=O)c12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.47
ACVR1 Q04771 1/20 0.46
RNASEH1 O60930 1/20 0.43
CCNB2 O95067 1/20 0.43
CCNE2 O96020 1/20 0.43
CDK1 P06493 1/20 0.43
CDK4 P11802 1/20 0.43
CCNB1 P14635 1/20 0.43
CCND1 P24385 1/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
CCNB3 Q8WWL7 1/20 0.43
PDE5A O76074 3/20 0.43
USP2 O75604 1/20 0.43
POLB P06746 1/20 0.41
TBXAS1 P24557 2/20 0.40
NAPRT Q6XQN6 1/20 0.40
PLA2G7 Q13093 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405327 0.88 KMT2A (0.61) ALDH1A1KMT2AACVR1RNASEH1PDE5A
SCHEMBL403048 0.81 ALDH1A1 (0.48) ALDH1A1KMT2ARNASEH1PDE5AUSP2
SCHEMBL405065 0.81 PDE5A (0.64) KMT2AACVR1RNASEH1CCNB2CCNE2
SCHEMBL400190 0.79 KDM4C (0.52) CCNB2CCNE2CDK1CDK4CCNB1
SCHEMBL405399 0.78 RNASEH1 (0.60) KMT2AACVR1RNASEH1PDE5APOLB
SCHEMBL401595 0.78 MAPT (0.47) ALDH1A1KMT2AACVR1RNASEH1CCNE2
SCHEMBL13892327 0.77 TNKS2 (0.57) ALDH1A1KMT2AACVR1POLB
SCHEMBL405915 0.77 PDE5A (0.58) ALDH1A1KMT2ARNASEH1CCNB2CCNE2
SCHEMBL406541 0.76 PDE5A (0.69) ALDH1A1KMT2ARNASEH1PDE5APOLB
SCHEMBL405407 0.76 POLB (0.57) ALDH1A1RNASEH1CCNE2CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050739-B1 QUINAZOLINE DERIVATIVE ASKA PHARM CO LTD (JP) 2016-07-06 EP disclosed
CN-101501007-B Quinazoline derivative ASKA PARMACEUTICAL CO LTD 2014-01-29 CN disclosed
US-8101624-B2 Quinazoline derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-24 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20090318478-A1 QUINAZOLINE DERIVATIVES ASKA PHARMACEUTICAL CO., LTD. 2009-12-24 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
CN-101557826-A Therapeutic agent for urinary tract disease ASKA PHARM CO LTD (JP) 2009-10-14 CN disclosed
CN-101501007-A Quinazoline derivative ASKA PARMACEUTICAL CO LTD (JP) 2009-08-05 CN disclosed
EP-2050739-A1 QUINAZOLINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD ALDH1A1 762/4885KMT2A 2820/4885ACVR1 4496/4885
US-20090318478-A1 QUINAZOLINE DERIVATIVES PDE9A, PDE3A, PDE5A ALDH1A1 235/4885KMT2A 3246/4885ACVR1 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.